Tests evaluating neutrophil activation
|
ENA-78 |
Epithelial neutrophil activating peptide |
Bowel epithelial cells; intestinal epithelial cells |
Stimulates the chemotaxis of neutrophils, possesses angiogenic properties |
[10, 21] |
HLE |
Human leucocytic elastase |
Activated neutrophils |
Plays a role in degenerative and inflammatory diseases through proteolysis of collagen-IV and elastin |
[6] |
MRP-8/MRP-14 or S100A8/A9 |
Calprotectin |
Cytoplasm of neutrophils and monocytes |
Antibacterial, antifungal, immunomodulatory, and antiproliferative action; a chemotactic factor for neutrophils; the fecal level is proportional to neutrophilic influx into the intestinal tract |
[1, 77] |
L |
Lactoferrin |
Neutrophils |
Takes part in acute inflammatory response; exhibits high affinity to iron making iron inaccessible to bacteria; fecal L increases significantly with bowel infiltration by neutrophils |
[10, 58] |
N |
Neopterine |
Monocytes and macrophages |
Inflammatory marker; may help predict the progress of the disease; useful to assess clinical activity of IBD |
[9] |
Serological markers
|
ANCAs |
Antineutrophil cytoplasmic antibodies |
|
High p-ANCA levels and antibodies to CBir1 have been associated with increased risk of pouchitis after colectomy in UC |
[70] |
cANCA |
Cytoplasmic |
Antibodies against granules of neutrophil cytoplasm |
Increase in UC |
|
sANCA |
Speckled |
|
Patients with CD and positive p-ANCA were less likely to respond to therapy with infliximab |
|
pANCA |
Peripheral-antinuclear cytoplasmic antibody |
|
Increase significantly in UC |
[74] |
ASCAs |
Anti-Saccharomyces cerevisiae antibodies |
|
The utility in diagnosing difficult cases of indeterminate colitis (IC) |
[74] |
Anti-OmpC |
Antiouter membrane protein C antibody |
|
OmpC pANCA, ASCA, and I2 altogether can be found in 80% of patients with CD |
[10] |
Hup-B |
Mycobacterial histone H1 homologue |
|
May represent the target antigen for pANCA |
[10] |
Anti-CBir1 flagellin |
Antibodies to bacterial flagellin |
|
May be a marker of Crohn's disease complicated by fistulas, perforations, or other serious problems |
[10] |
PAB |
Pancreatic antibody (an antibody to a trypsin-sensitive protein in pancreatic secretions) |
|
PAB is positive in 20%–40% of CD cases and 5% of UC cases; PAB expression may exhibit racial differences |
[6] |
Anti-I2 |
Antibodies to Pseudomonas fluorescens-associated sequence I2 |
|
IgA anti-I2 is positive in 55% of CD cases, 10% of UC cases, and 20% of non-IBD colitis cases; anti-I2 has also been found in patients with other inflammatory enteritis |
[10] |
Platelet abnormalities
|
|
β-Tromboglobulin |
Platelets |
Increased during active IBD |
[20] |
|
P selectin |
Endothelial cells |
Serum level of soluble platelet selectin (sP-selectin) is increased during progression of IBD; in inactive CD, serum levels of sP-selectin are lower than in controls; in patients with ulcerative colitis, serum concentrations of sP-selectin and IL-6 are significantly higher compared to healthy subjects |
[34, 49] |
PAF |
Platelet activation factor |
Platelets |
Increased in patients with IBD |
[36] |
TF(+) MPs |
Procoagulant microparticles |
Microparticles circulating into the blood |
Indicates for hypercoagulability of blood in IBD patients, which is associated with the appearance of thrombin in the vasculature of the intestine and extraintestinal tissues |
[33] |